Leveraging Protein Scavenging in RAS Cancers to Enable Targeted Drug Delivery & Expand Therapeutic Possibilities Beyond Direct RAS Inhibition
- Highlighting a fundamental metabolic dependency in mutant RAS cancers by educating audiences on protein scavenging as a shared tumor vulnerability
- Demonstrating efficient tumor delivery and strong safety across multiple RAS-driven models using a protein drug-conjugate platform
- Expanding treatment possibilities by enabling combination and post-resistance strategies alongside next-generation RAS inhibitors